TO THE QUESTION OF DIFFERENTIAL DIAGNOSIS OF T CELL SKIN LYMPHOMAS


Cite item

Full Text

Abstract

Cutaneous T cell lymphomas (CTCL) are a clinically and morphologically heterogeneous group of cutaneous malignant tumors, caused by monoclonal proliferation of lymphoid tissue cells in the skin. They are responsible for about 80% of all primary cutaneous lymphomas, while cutaneous lymphomas are responsible for 2% of all dermatological diseases. The incidence of CTCL is now increasing all over the world. For this reason, CTCL has to be diagnosed on the early stage to improve course of the disease. Mycosis fungoides, the most frequent CTCL variant, is usually diagnosed basing on clinical, histological, immunohistochemical and molecular findings. However, it can imitate other chronic dermatoses, which makes it difficult to diagnose. The article presents a review of the current literature data on new diagnostic markers of cutaneous T-cell lymphomas.

About the authors

Olga Yu. Olisova

I. M. Sechenov First Moscow State Medical University (Sechenov University)

Email: olisovaolga@mail.ru
Department of Skin and Venereal Diseases Moscow, 119991, Russian Federation

D. R Amshinskaya

I. M. Sechenov First Moscow State Medical University (Sechenov University)

Department of Skin and Venereal Diseases Moscow, 119991, Russian Federation

E. M Anpilogova

I. M. Sechenov First Moscow State Medical University (Sechenov University)

Department of Skin and Venereal Diseases Moscow, 119991, Russian Federation

References

  1. Олисова О.Ю., Сыдиков А.А., Чупров И.Н., Горенкова Л.Г., Черныш С.А., Доронин В.А. и др. Эритродермическая форма грибовидного микоза: алгоритм диагностики и лечения. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2018; 11(4): 295-302. doi: 10.21320/2500-2139-2018-11-4-295-302.
  2. Peterson E., Weed J., Lo Sicco K., Latkowski J.A. Cutaneous T-cell lymphoma a difficult diagnosis demystified. Dermatol. Clin. 2019; 37(4): 455-69. doi: 10.1016/j.det.2019.05.007.
  3. Foss F.M., Girardi M. Mycosis fungoides and Sezary syndrome. Hematol. Oncol. Clin. N. Am. 2017; 31(2): 297-315. doi: 10.1016/j.hoc.2016.11.008.
  4. Pulitzer M. Cutaneous T-cell lymphoma. Clin. Lab. Med. 2017; 37(3): 527-46. doi: 10.1016/j.cll.2017.06.006.
  5. Ralfkiaer U., Lindahl L.M., Litman T., Gjerdrum L.M., Ahler C.B., Gniadecki R., et al. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. Anticancer Res. 2014; 34(12): 7207-17.
  6. Hristov A.C., Tejasvi T., Wilcox R.A. Mycosis fungoides and Sezary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2019. doi: 10.1002/ajh.25577.
  7. Shen X., Wang B., Li K. Wang L., Zhao X., Xue F., et al. MicroRNA signatures in diagnosis and prognosis of cutaneous T-cell lymphoma. J. Invest. Dermatol. 2018; 138(9): 2024-32. doi: 10.1016/j.jid.2018.03.1500.
  8. Martinez-Escala M.E., Choi J. Are microRNAs key to developing biomarkers for cutaneous T-cell lymphoma? J. Invest. Dermatol. 2018; 138(9): 1906-8. doi: 10.1016/j.jid.2018.04.012.
  9. Kulow B.F., Cualing H., Steele P., VanHorn J., Breneman J.C., Mutasim D.F., Breneman D.L. Progression of cutaneous B-cell pseudolymphoma to cutaneous B-cell lymphoma. J. Cutan. Med. Surg. 2002; 6(6): 519-28.
  10. Riyaz N., Sasidharanpillai S., Aravindan K.P., Nobin B.K., Raghavan N.T., Nikhila P.K. Phenytoin induced cutaneous B cell pseudolymphoma. Indian J. Dermatol. 2015; 60(5): 522. doi: 10.4103/0019-5154.164437.
  11. Miguel D., Peckruhn M., Elsner P. Treatment of cutaneous pseudolymphoma: a systematic review. Acta Derm. Venereol. 2018; 98(3): 310-7. doi: 10.2340/00015555-2841.
  12. Bastidas Torres A.N., Cats D., Mei H., Szuhai K., Willemze R., Vermeer M., Tensen C.P. Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides. Genes Chromosomes Cancer. 2018; 57(12): 653-64. doi: 10.1002/gcc.22679.
  13. Sibbessen N.A., Kopp K.L., Litvinov I.V., Jonson L., Willerslev-Olsen A., Fredholm S., et al. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-cell lymphoma. Oncotarget. 2015; 6(24): 20555-69.
  14. Воронцова А.А., Карамова А.Э., Знаменская Л.Ф. Современные представления о патогенезе грибовидного микоза. Онкогематология. 2018; 13(3): 39-46. doi: 10.17650/1818-8346-2018-13-3-39-46.
  15. Nishikomori R., Usui T., Wu C.Y., Morinobu A., O’Shea J., Strober W. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12Rβ2 chain expression and signaling. J. Immunol. 2002; 169(8): 4388-98.
  16. Олисова О.Ю., Грекова Е.В., Варшавский В.А., Горенкова Л.Г., Алексеева Е.А., Залетаев Д.В. и др. Современные возможности дифференциальной диагностики бляшечного парапсориаза и ранних стадий грибовидного микоза. Архив патологии. 2019; 81(1): 9-17. doi: 10.17116/patol2019810119.
  17. Низяева Н.В., Кан Н.Е., Тютюнник В.Л., Ломова Н.А., Наговицына М.Н., Прозоровская К.Н. и др. МикроРНК как важные диагностичеcкие предвестники развития акушерской патологии. Вестник РАМН. 2015; 70(4): 484-92. doi: 10.15690/vramn.v70.i4.1416.
  18. Аушев В.Н. МикроРНК: малые молекулы с большим значением. Клиническая онкогематология. 2015; 8(1): 1-12.
  19. Szelenberger R., Kacprzak M., Saluk-Bijak J., Zielinska M., Bijak M. Plasma microRNA as a novel diagnostic. Clin. Chim. Acta. 2019; 499: 98-107. doi: 10.1016/j.cca.2019.09.005.
  20. Малек А.В., Берштейн Л.М. МикроРНК: половые гормоны, гормональный канцерогенез, гормоночувствительность опухолевой ткани. Успехи молекулярной онкологии. 2015; 2(1): 004-012. doi: 10.17650/2313-805X.2015.2.1.004-012.
  21. Marosvari D., Teglasi V., Csala I., Marschalko M., Bodor C., Timar B., et al. Altered microRNA expression in folliculotropic and transformed mycosis fungoides. Pathol. Oncol. Res. 2015; 21(3): 821-5. doi: 10.1007/s12253-015-9897-8.
  22. Persson J.L. miRNA in mycosis fungoides and skin inflammation. APMIS. 2013; 121(11): 1017-9. doi: 10.1111/apm.12186.
  23. Rittig A.H., Lindahl L.M., Johansen C., Celis P., Odum N., Iversen L., Litman T. The microRNA expression profile differs between erythrodermic mycosis fungoides and Sezary syndrome. Acta Derm. Venereol. 2019. doi: 10.2340/00015555-3306.
  24. Kohnken R., Mishra A. MicroRNAs in cutaneous T-cell lymphoma: the future of therapy. J. Invest. Dermatol. 2019; 139(3): 528-34. doi: 10.1016/j.jid.2018.10.035.
  25. Malpeli G., Barbi S., Greco C., Zupo S., Bertolaso A., Scupoli M., et al. MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. Oncotarget. 2018; 9(28): 19961-79. doi: 10.18632/oncotarget.24987.
  26. Yasui K., Izumida M., Nakagawa T., Kubo Y., Hayashi H., Ito T., et al. MicroRNA-3662 expression correlates with antiviral drug resistance in adult T-cell leukemia/lymphoma cells. Biochem. Biophys. Res. Commun. 2018; 501(4): 833-7. doi: 10.1016/j.bbrc.2018.04.159.
  27. Жуков А.С., Белоусова И.Э., Самцов А.В. Иммунологические и молекулярногенетические механизмы развития грибовидного микоза. Вестник дерматологии и венерологии. 2015; (4): 42-50. doi: 10.25208/0042-4609-2015-0-4-42-50.
  28. Jiang X., Cheng Y., Hu C., Zhang A., Ren Y., Xu X. MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5. Leuk Lymphoma. 2019; 60(7): 1709-20. doi: 10.1080/10428194.2018.1543875.
  29. Dusilkova N., Basova P., Polivka J., Kodet O., Kulvait V., Pesta M., et al. Plasma miR-155, miR-203, and miR-205 are biomarkers for monitoring of primary cutaneous T-cell lymphomas. Int. J. Mol. Sci. 2017; 18(10): pii E2136. doi: 10.3390/ijms18102136.
  30. Tian Z., Shiyu Z., Tao W., Li L., Yuehua L., Hongzhong J. Lymphoma or pseudolymphoma: a report of six cases and review of the literature. Dermatol. Ther. 2019; 32(4): e12807. doi: 10.1111/dth.12807.

Copyright (c) 2019 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies